---
title: Effect of Epinephrine on Systemic Absorption of Mepivacaine in Uremic Patients
nct_id: NCT01533545
overall_status: TERMINATED
phase: NA
sponsor: Rigshospitalet, Denmark
study_type: INTERVENTIONAL
primary_condition: Renal Insufficiency, Chronic
countries: Denmark
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT01533545.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT01533545"
ct_last_update_post_date: 2014-04-16
last_seen_at: "2026-05-12T06:26:13.285Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Effect of Epinephrine on Systemic Absorption of Mepivacaine in Uremic Patients

**Official Title:** Effect of Epinephrine on Systemic Absorption of Mepivacaine Administered for Brachial Plexus Block in Patients With Chronic Renal Insufficiency

**NCT ID:** [NCT01533545](https://clinicaltrials.gov/study/NCT01533545)

## Key Facts

- **Status:** TERMINATED
- **Why Stopped:** Slow recruitment
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 16
- **Lead Sponsor:** Rigshospitalet, Denmark
- **Conditions:** Renal Insufficiency, Chronic
- **Start Date:** 2012-09
- **Completion Date:** 2014-09
- **CT.gov Last Update:** 2014-04-16

## Brief Summary

The aim of this study is to determine the effect of epinephrine on systemic absorption of local anaesthetic mepivacaine administered for brachial plexus block in uremic patients scheduled for creation or repair of an arteriovenous fistula. Furthermore, an impact of epinephrine on the central circulation and peripheral tissue oxygenation will be evaluated.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* patient acceptance of regional anaesthesia

Exclusion Criteria:

* peripheral arteriosclerosis
* diabetes mellitus
* bleeding disorder
* infection at the puncture site
* allergy to mepivacaine
* pregnancy
```

## Arms

- **Plain mepivacaine** (ACTIVE_COMPARATOR)
- **Mepivacaine with epinephrine** (ACTIVE_COMPARATOR)

## Interventions

- **Mepivacaine with epinephrine** (DRUG) — Ultrasound-guided infraclavicular brachial plexus block with mepivacaine 400 mg (10 mg/mL) mixed with epinephrine 200 μg (5 μg/mL)
- **Plain mepivacaine** (DRUG) — Ultrasound-guided infraclavicular brachial plexus block with plain mepivacaine 400 mg (10 mg/mL)

## Primary Outcomes

- **Plasma concentration of mepivacaine** _(time frame: 0, 5, 10, 20, 30, 45, 60, 120, and 180 min after blockade)_

## Secondary Outcomes

- **Central circulation** _(time frame: 0, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, and 60 min after blockade)_
- **Peripheral tissue oxygenation** _(time frame: 0, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, and 60 min after blockade)_
- **Cardiotoxicity of local anesthetic** _(time frame: 0, 5, 10, 20, 30, 45, and 60 min after blockade)_
- **Neurotoxicity of local anesthetic** _(time frame: Continuously for 1 hour after blockade)_

## Locations (1)

- Rigshospitalet, Copenhagen, Denmark

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.whyStopped` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.rigshospitalet|copenhagen||denmark` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT01533545.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT01533545*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*